EquivaBone is now additionally indicated for use in posterolateral spine fusion, combining the certified osteoinductivity of DBM with the handling and hard setting characteristics of Etex calcium phosphate osteoconductive scaffold.
The clearance also allows EquivaBone to be mixed with autologous blood to create a viscous putty can then be molded and packed or injected into a defect.
Read Etex’s release on FDA approval of EquivaBone.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
